News & Updates

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023 by

In individuals with hepatorenal syndrome (HRS) compounded by alcoholic hepatitis (AH), treatment with the synthetic, long-acting vasopressin analogue terlipressin led to the achievement of verified HRS reversal, a subgroup analysis of the phase III CONFIRM trial has shown.

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023

New data fortify obeticholic acid role in NASH treatment

29 May 2023 by

In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).

New data fortify obeticholic acid role in NASH treatment

29 May 2023

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

25 May 2023 by

The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

25 May 2023

SGLT2 inhibitors reduce HCC risk in T2DM patients with CHB

18 May 2023 by

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk of incident hepatocellular carcinoma (HCC) in patients with coexisting type 2 diabetes mellitus (T2DM) and chronic hepatitis B (CHB), a territory-wide cohort study in Hong Kong has shown.

SGLT2 inhibitors reduce HCC risk in T2DM patients with CHB

18 May 2023

SBRT effective, well tolerated for unresectable liver metastases

15 May 2023 by

A retrospective study in Hong Kong has shown that stereotactic body radiotherapy (SBRT) is an effective and well-tolerated treatment for patients with unresectable liver metastases.

SBRT effective, well tolerated for unresectable liver metastases

15 May 2023

Type 2 hepatitis no different from type 1 in terms of outcome

02 May 2023

Liver outcomes do not differ between types 1 and 2 autoimmune hepatitis presenting in childhood, reports a recent study.

Type 2 hepatitis no different from type 1 in terms of outcome

02 May 2023

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

26 Apr 2023

Adherence to a diet rich in protein and unsaturated fatty acids (UFAs) helps improve liver fat and lipid metabolism in people at risk of unhealthy ageing, a recent study has shown.

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

26 Apr 2023

Adverse events occur in two-thirds of NASH patients on placebo

24 Apr 2023

Nearly two in three participants in the placebo arm of nonalcoholic steatohepatitis (NASH) randomized clinical trials (RCTs) experience an adverse event (AE), while one in 10 have a serious AE, according to a pooled analysis of studies with NASH placebo.

Adverse events occur in two-thirds of NASH patients on placebo

24 Apr 2023

More movement tied to lower risks of hospitalization for common health conditions

18 Apr 2023 by

Individuals engaging in more physical activities had lower risks of hospitalization for a multitude of common health conditions, according to a prospective cohort study using data from the UK Biobank.

More movement tied to lower risks of hospitalization for common health conditions

18 Apr 2023

ARO-HSD well tolerated in NASH patients

02 Apr 2023

An RNA interference therapy, ARO-HSD, is tolerable at ≤200-mg doses, suggests a phase I/II study. Short-term treatment with ARO-HSD results in decreases in hepatic HSD17β13 mRNA and protein expression, which is complemented by alanine aminotransferase reductions.

ARO-HSD well tolerated in NASH patients

02 Apr 2023

News & Updates

Filter by Specialty:

Specialty:

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

New data fortify obeticholic acid role in NASH treatment

New data fortify obeticholic acid role in NASH treatment

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

SGLT2 inhibitors reduce HCC risk in T2DM patients with CHB

SGLT2 inhibitors reduce HCC risk in T2DM patients with CHB

SBRT effective, well tolerated for unresectable liver metastases

SBRT effective, well tolerated for unresectable liver metastases

Type 2 hepatitis no different from type 1 in terms of outcome

Type 2 hepatitis no different from type 1 in terms of outcome

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

Adverse events occur in two-thirds of NASH patients on placebo

Adverse events occur in two-thirds of NASH patients on placebo

More movement tied to lower risks of hospitalization for common health conditions

More movement tied to lower risks of hospitalization for common health conditions

ARO-HSD well tolerated in NASH patients

ARO-HSD well tolerated in NASH patients